Abstract Mixed connective tissue disease (MCTD) is rare in pediatric rheumatic diseases. Pulmonary arterial hypertension (PAH) associated with MCTD usually progresses gradually and is difficult to note at the asymptomatic phase. We report a 11-year-old girl with MCTD complicated with rapidly progressive PAH. Although PAH was not detected by echocardiogram or chest CT scan at the initial examination, it became clear in 1 year and suddenly came to cardiac arrest during an invasive procedure. She was successfully treated with extracorporeal assist and both vasodilative and immunosuppressive medication. A combination of echocardiogram and plasma BNP levels could be a useful marker for the follow-up of such cases. PAH could develop early in the course of pediatric MCTD and needs attention to unexpected acute exacerbation, especially under emotional stress.
Introduction
Mixed connective tissue disease (MCTD) is characterized by Raynaud phenomenon (RP) or swollen hands, overlapping clinical features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and polymyositis/dermatomyositis in conjunction with the presence of anti-ribonucleoprotein (RNP) antibodies [3] . MCTD is rare in children and constitutes 0.6 % of pediatric rheumatic diseases [5] . The poor prognosis is associated with the presence of interstitial lung diseases or pulmonary arterial hypertension (PAH). PAH is more severe in adult MCTD; however, it tends to progresses gradually [1] . Here, we report an 11-year-old girl with rapidly progressive PAH associated with MCTD.
Case report
A 10-year-old Japanese girl was referred to our hospital because of RP since the age of 9 years. She also showed swollen fingers. Laboratory findings were as follows: white blood cell count 4.1× 10 9 /L with normal differentiation, hemoglobin 118 g/L, platelet count 216×10 9 /L, erythrocyte sedimentation rate 32 mm/h, C-reactive protein<0.2 mg/L (normal range, <3.9), C3 1.00 g/L (normal range, 0.86- . SLE-specific autoantibodies such as anti-double-stranded DNA and anti-Smith antibodies or SSc-specific antibodies such as anti-topoisomerase antibodies were all negative. Pulmonary function test (PFT) showed slightly decreased percentage of diffusing capacity of carbon monoxide (%DLCO, 65.6 %) and normal % vital capacity (%VC, 82 %). There was no evidence of PAH or interstitial pneumonia (IP) on either echocardiographic study or chest computed tomography (CT) scan. Plasma B-type natriuretic peptide (BNP) level was 20.5 pg/mL (normal range, <18.4). The chest X-ray showed normal cardiothoracic ratio (CTR) 50 %. At 4 months later, she showed elevated serum creatinine kinase and thus fulfilled the classification criteria of MCTD according to the Ministry of Health, Labor, and Welfare of Japan [4] . At 9 months later, at the age of 11 years, she visited our hospital because of fever, vomitting, and general fatigue lasting for 2 days. She was alert but heavily sweated with cold extremities. Biophysical monitoring showed blood pressure 126/86 mmHg, body temperature 37.1°C, and SpO 2 98 % on room air. The chest X-ray showed cardiomegaly (CTR 68 %) but no apparent infiltrative shadows. Echocardiography demonstrated right ventricular dilatation, paradoxical movement of the interventricular septum, and tricuspid regurgitation. These findings suggested PAH rather than other causes of pulmonary hypertension such as interstitial lung diseases. Because of failure to access the peripheral vein, we tried to insert a central venous catheter via the femoral vein. During the procedure, electrocardiography showed wide-QRS bradycardia and subsequently asystole. She needed percutaneous cardiopulmonary support for 7 days followed by extracorporeal membrane oxygenation for 4 days. On the sixth hospital day, systolic pulmonary arterial pressure assessed by right heart catheterization was 60 mmHg.
Plasma BNP level was 1,146.3 pg/ mL. PAH responded to the combination therapy with epoprostenol sodium, bosentan hydrate, and sildenafil citrate (Fig. 1) . Disseminated intravascular coagulation syndrome, pulmonary hemorrhage, and acute renal failure developed but gradually recovered over time. During the course, she lost the distal phalanx of the left forefinger due to ischemic necrosis and suffered from paraplegia, possibly due to infarct of the anterior spinal artery. Although mild ground-glass opacity suggesting IP or lung edema was observed on chest CT scan 1 month after her admission, it subsided following a combination therapy with methylprednisolone pulse therapy (30 mg/kg/dose for three consecutive days) followed by high-dose prednisolone (PSL) (2 mg/kg/day) and three courses of monthly intravenous cyclophosphamide therapy (500 mg/m 2 ). She was finally discharged from the hospital after 10 months of hospitalization on daily PSL 10 mg/day, azathiopurin 50 mg/day, phosphodiesterase V (PDE-5) inhibitor (tadalafil 20 mg/day), endothelin receptor antagonist (bosentan 62.5 mg/day), and prostacyclin analog (beraprost 300 μg/day). A follow-up echocardiography approximated a systolic pulmonary arterial pressure of 30-35 mmHg. BNP levels decreased and remained within normal range despite residual mild cardiomegaly (CTR 60 %). Fig. 1 Treatment and chronological changes in BNP levels. Extracorporeal assist was performed for 11 days since her admission to our hospital. BNP level was first measured on the fifth hospital day during extracorporeal assist. Soon after discontinuation of extracorporeal assist, BNP level was 1,146.3 pg/ mL. PCPS percutaneous cardiopulmonary support, ECMO extracorporeal membrane oxygenation
Discussion
Although PAH is a life-threatening complication of MCTD, it is difficult to be noted at the asymptomatic phase because early PAH symptoms mimic those of the underlying MCTD [10] . Echocardiography is very helpful for screening for PAH. Heart catheterization is a gold standard for the diagnosis of PAH but is invasive and should be considered when PAH is suspected. PFT is a noninvasive diagnostic test to detect obstructive or restrictive diseases. Particularly, low and decreasing DLCO and %VC/%DLCO ratio≥1.4 are a valuable predictor of the PAH and useful for differential diagnosis from interstitial lung diseases in connective tissue disease (CTD) [9, 11] . Our case showed a low %VC/%DLCO ratio (1.25) and normal echocardiographic and chest CT scan findings at initial examination. Likewise, BNP which is primarily produced by cardiomyocytes of the ventricles of the heart, a biochemical marker for impaired overall cardiac function, was initially near normal levels. These suggest that PAH progressed very rapidly within 1 year after the initial examination. Annual screening of PAH by echocardiography, PFT, and BNP has been recommended in CTD [11] . However, given that PAH may rapidly progress as in our case, routine evaluation should be performed more frequently, e.g., every six months in pediatric MCTD.
Inflammation-mediated organizing vasculopathy are thought to be involved in the progression of CTDassociated PAH. Immunological and/or inflammatory endothelial damage initially leads to vascular obliteration characterized by intimal proliferation, medial hyperplasia, and finally irreversible fibrosis of the small pulmonary arteriole walls [2, 6] . This is supported by the fact that the survival rate of PAH has been improved by an early diagnosis and the prompt use of immunosuppressants in combination with modern PAHspecific vasodilative drugs such as prostanoid, PDE-5 inhibitors, and endothelin receptor antagonist [7, 8] . Consistent with this, the response of PAH to the treatment with both immunosuppressants and vasodilative drugs suggests that the PAH in our case was, at least partially, still reversible. In addition to the slowly progressive inflammatory mechanisms, functional vasospasm due to sympathetic overactivity could be a cause of acute exacerbation of PAH. Invasive procedures could have triggered excessive vasospasms on the basis of underlying subclinically progressed PAH in our case.
Conclusion
Rapidly progressive PAH complicating MCTD was successfully treated with extracorporeal circulation and both vasodilative and immunosuppressive medication. PAH could develop early in the course of pediatric MCTD and needs attention to unexpected acute exacerbation, especially under emotional stress.
